Everest Medicines (1952.HK) Earnings Analysis
Everest Medicines (1952.HK) next reports earnings on 2026-09-02, consensus EPS -1.0738 HKD. Last quarter (2026-03-24) it missed with EPS -0.13355 HKD vs 0.1113 HKD est (-220%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -24.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1952.HK next report earnings?
| Next earnings date | 2026-09-02 |
|---|---|
| Consensus EPS estimate | -1.0738 HKD |
| Revenue estimate | 1.59B |
1952.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-24 | -0.13355 HKD | 0.1113 HKD | -220% | Miss |
| 2025-08-27 | -0.84377 HKD | -1.10676 HKD | +23.8% | Beat |
| 2025-03-24 | -1.35172 HKD | -1.34108 HKD | -0.8% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
1952.HK valuation and analyst view
| Trailing P/E | -24.55 |
|---|---|
| Trailing EPS | -0.88684 HKD |
| Price / book | 1.40 |
| Dividend yield | 0.00% |
| Market cap | 9.04B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Everest Medicines (1952.HK)'s next earnings date?
Everest Medicines is next scheduled to report on 2026-09-02, with a consensus EPS estimate of -1.0738 HKD and revenue estimate of 1.59B.
Did 1952.HK beat earnings last quarter?
In its 2026-03-24 report, 1952.HK posted EPS of -0.13355 HKD versus a 0.1113 HKD estimate — a miss of 220%.
What is 1952.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 1952.HK beat estimates 1 times (33%).
What is 1952.HK's current P/E ratio and EPS?
1952.HK trades at a trailing P/E of -24.55 on trailing EPS of -0.8868431784389703 HKD.
What do analysts rate 1952.HK?
1952.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.